Plans for a new larger state-of-the-art facility to meet growing demand

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for

Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth

£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model

hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured

hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced

SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).

Transformational year with record EBITDA underlining strong operational delivery

Positive results from influenza human challenge study conducted by hVIVO